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Abstract 
Locally advanced non-small cell lung cancer (NSCLC) continues to be a challenging disease to treat. With high rates of 
both local and distant failures, there is significant interest in finding more biologically active chemotherapy regimens 
that can contribute to reduce both failures. The phase III PROCLAIM trial, recently published in the Journal of Clinical 
Oncology entitled “PROCLAIM: randomized phase III trial of pemetrexed–cisplatin or etoposide–cisplatin plus thoracic 
radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung 
cancer”, compared two different chemotherapy regimens given concurrently with radiotherapy in patients with stage 
III non-squamous lung cancer: pemetrexed plus cisplatin versus cisplatin plus etoposide. Both groups received con-
solidation chemotherapy. After enrolling 598 of planned 600 patients, the study was stopped early due to futility as no 
difference was seen in the primary end-point of overall survival. Since PROCLAIM was designed as a superiority trial, 
these results suggest that pemetrexed regimens do not offer a clinical advantage over standard cisplatin plus etopo-
side. There are some subpopulations who might still benefit from pemetrexed, especially if clinicians are concerned 
about myelosuppression-related adverse events. Future trials are needed to investigate novel biologic agents and 
irradiation techniques that can result in more durable local and distant disease control in locally advanced NSCLC.
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Lung cancer continues to be the leading cancer world-
wide [1], with non-small cell lung cancer (NSCLC) repre-
senting approximately 85% of all lung cancers diagnosed 
in the United States [2]. However, overall outcomes in 
locally advanced NSCLC continue to lag behind improve-
ments achieved in other cancer sites as indicated by the 
5-year survival rate of patients with stage IIIA and IIIB 
NSCLC ranging from 2% [3] to 18% [4]. Regardless, the 
standard of care for locally advanced NSCLC remains 
concurrent radiotherapy, and yet the exact details of the 
concurrent chemotherapy continue to be the subject of 
much debate [5].
The question of sequential vs. concurrent chemother-
apy has already been addressed in multiple randomized 
trials and meta-analyses [5–7]. Induction chemother-
apy prior to concurrent chemoradiation has not shown 
significant benefit and is not considered standard in the 
algorithm of definitive treatment [8, 9]. Platinum-based 
doublets have been used in the majority of modern trials, 
including cisplatin plus etoposide [10] or weekly carbo-
platin plus paclitaxel [8]. Other attempts at modification 
of chemotherapy regimen, including consolidation chem-
otherapy following concurrent chemoradiation, have 
not shown a meaningful benefit either [11, 12]. Despite 
many advances, the rates of distant and local disease pro-
gression remain high, and efforts to find new areas for 
improvement have been numerous.
One of these efforts includes the use of pemetrexed, 
which is a potent anti-folate agent [13] and is currently 
approved for first-line treatment of metastatic non-squa-
mous lung carcinoma and unresectable mesothelioma 
[14]. It has also shown efficacy in comparison to other 
regimens in the setting of advanced or metastatic non-
squamous NSCLC [15]. The favorable toxicity profile of 
pemetrexed with concurrent irradiation, as well as its 
greater activity in metastatic non-squamous NSCLC, has 
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raised the question of its possible role in definitive treat-
ment of locally advanced NSCLC.
The PROCLAIM trial, recently published in the Journal 
of Clinical Oncology entitled “PROCLAIM: randomized 
phase III trial of pemetrexed-cisplatin or etoposide-cispl-
atin plus thoracic radiation therapy followed by consoli-
dation chemotherapy in locally advanced nonsquamous 
non-small-cell lung cancer”, aimed to answer some of 
the above questions [16]. The trial enrolled patients with 
unresectable, stage III, non-squamous NSCLC who had 
an Eastern Cooperative Oncology Group performance 
status (PS) of 0 or 1. Some of the exclusion criteria 
included previous systemic chemotherapy or inability 
to meet dosimetric irradiation criteria, specifically if the 
volume of whole lung receiving 20 Gy or more exceeded 
35%. Patients were randomly assigned on a 1:1 basis to 
either treatment group with the stratification criteria 
including PS, stage (IIIA vs. IIIB), and baseline positron 
emission tomography (PET) scan. The pemetrexed group 
received pemetrexed and cisplatin along with concurrent 
thoracic radiotherapy followed by four cycles of consoli-
dation pemetrexed therapy. The etoposide group received 
cisplatin plus etoposide concurrently with radiotherapy 
followed by consolidation chemotherapy consisting of 
two cycles of a platinum-based doublet regimen. Tho-
racic radiotherapy consisted of 60–66 Gy, depending on 
meeting specific dose criteria, in 30–33 fractions. The 
primary end-point was designated as the overall sur-
vival (OS), with the assumptions of a superiority trial. A 
total of 600 patients were planned for enrollment, while 
assuming a minimum of 355 deaths and an 80% power to 
detect a hazard ratio (HR) of 0.74.
Overall, 598 patients were enrolled in the PROCLAIM 
trial with a median follow-up of approximately 23 months 
for both regimens. In the pemetrexed group, 80.9% of 
patients were able to complete treatment as opposed to 
74.3% in the etoposide group. Both groups received simi-
lar dosages of thoracic radiotherapy in a similar pattern. 
Both regimens were well tolerated, but the pemetrexed 
group showed lower rates of neutropenia and febrile 
neutropenia than the etoposide group (18.4% vs. 28.7%, 
P = 0.005). Interestingly, the rate of grade 2 pneumoni-
tis was significantly higher in the pemetrexed group than 
the etoposide group (11.0% vs. 5.5%). The primary end-
point OS was not different between the two groups after 
173 deaths (HR = 0.98, 95% confidence interval = 0.79–
1.20, P =  0.831). The study was therefore stopped after 
the interim analysis after 798 patients were enrolled for 
futility of superiority of the pemetrexed group compared 
with the etoposide group.
Given the results of this trial, it appears that cisplatin 
plus etoposide remains the standard of care for non-
squamous NSCLC. Although the pemetrexed group 
showed an overall better hematological toxicity pro-
file compared with the etoposide regimen, it might be 
tempting to argue that pemetrexed plus cisplatin could 
be used in non-squamous NSCLC for concurrent treat-
ment. However, it is important to keep in mind that even 
after nearly half of anticipated deaths, there was not 
even a trend for improvement in OS with pemetrexed. It 
is difficult to imagine that a HR of 0.74 could have been 
reached, even with a larger number of events.
There were some issues with the study that might have 
affected the overall outcomes in both groups. Initial posi-
tron emission tomography (PET) scan was not required 
of all patients. Furthermore, 4-dimensional computed 
tomography (CT) simulation and intensity-modulated 
radiation therapy, which are now frequently used as cor-
nerstones of thoracic radiotherapy, were allowed but 
not required in the study. The consolidation regimens 
also varied widely in the etoposide group and divided 
between 3 different regimens, increasing the heteroge-
neity in that group. It is conceivable that the addition of 
different chemotherapeutic agents in the etoposide group 
raised the response rates and helped mask the superior-
ity of pemetrexed, as essentially the trial was measuring 
continuation versus switch consolidation. In addition, 
approximately a quarter of the patients in the etoposide 
group eventually received pemetrexed when they pro-
gressed. Lastly, the anticipated number of deaths and HR 
was most likely set too high during the study design, min-
imizing any potential effect in a smaller population.
The PROCLAIM trial, while not demonstrating the 
superiority of pemetrexed plus cisplatin over cisplatin 
plus etoposide given concurrently with radiotherapy, 
established both regimens as reasonable alternatives for 
oncologists to consider. The pemetrexed regimen causes 
less hematological toxicity and does not cause alopecia, 
as well as requiring fewer visits to the infusion center, 
which could provide the oncologist with practical rea-
sons choosing this regimen.
Many questions still remain in the treatment of locally 
advanced NSCLC. The rates of local relapse (37.3% in 
the pemetrexed group vs. 45.8% in the etoposide group) 
and distant metastases (31% in the pemetrexed group 
vs. 37% in the etoposide group) seen in the PROCLAIM 
trial point towards a better need for both local and dis-
tant disease control if meaningful gains are to be made 
in the treatment of locally advanced NSCLC. There are 
multiple ongoing studies investigating new strategies 
for better local control including using metformin as a 
radiosensitizer (NRG-LU001), photon vs. proton thoracic 
radiotherapy (RTOG 1308), and individualized adoptive 
radiotherapy by using a during-treatment PET (RTOG 
1106). Immunotherapy has also started to play a prom-
ising role in the treatment of advanced lung cancer, and 
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recent data have shown that it can contribute to improve-
ments in outcomes. In the phase III START trial, anti-
Mucin 1 agent tecemotide showed an improvement in 
OS compared with placebo in patients who had com-
pleted concurrent chemoradiation [17].
To make significant inroads in the treatment of locally 
advanced NSCLC, novel treatment strategies are needed 
given the minimal gains made recently in terms of pro-
longing OS. Now that ample evidence exists regard-
ing the correct sequence of chemotherapy in locally 
advanced NSCLC and the most effective agents, future 
trials should direct their focus towards finding novel bio-
logic agents and irradiation strategies that can contribute 
to both local and distant control.
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